Compared to other therapeutic areas, CNS drug candidates have a lower probability of success and a longer development path. Since even some of the largest pharmaceutical companies in the world do not consider CNS a core therapeutic area for research and development spend, Paul L. Greene of INC Research looks into the factors that have led to this time that the industry has a discussion of how Ockham’s Razor can be applied to CNS clinical design.